TY - JOUR
T1 - Structural Characterization of the Aurora Kinase B “DFG-flip” Using Metadynamics
AU - Lakkaniga, Naga Rajiv
AU - Balasubramaniam, Meenakshisundaram
AU - Zhang, Shuxing
AU - Frett, Brendan
AU - Li, Hong yu
N1 - Publisher Copyright:
© 2019, American Association of Pharmaceutical Scientists.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Aurora kinase B (AKB), a Ser/Thr kinase that plays a crucial role in mitosis, is overexpressed in several cancers. Clinical inhibitors targeting AKB bind to the active DFG “in” conformation of the kinase. It would be beneficial, however, to understand if AKB is susceptible to type II kinase inhibitors that bind to the inactive, DFG “out” conformation, since type II inhibitors achieve higher kinome selectivity and higher potency in vivo. The DFG “out” conformation of AKB is not yet experimentally determined which makes the design of type II inhibitors exceedingly difficult. An alternate approach is to simulate the DFG “out” conformation from the experimentally determined DFG “in” conformation using atomistic molecular dynamics (MD) simulation. In this work, we employed metadynamics (MTD) approach to simulate the DFG “out” conformation of AKB by choosing the appropriate collective variables. We examined structural changes during the DFG-flip and determined the interactions crucial to stabilize the kinase in active and inactive states. Interestingly, the MTD approach also identified a unique transition state (DFG “up”), which can be targeted by small molecule inhibitors. Structural insights about these conformations is essential for structure-guided design of next-generation AKB inhibitors. This work also emphasizes the usefulness of MTD simulations in predicting macromolecular conformational changes at reduced computational costs.
AB - Aurora kinase B (AKB), a Ser/Thr kinase that plays a crucial role in mitosis, is overexpressed in several cancers. Clinical inhibitors targeting AKB bind to the active DFG “in” conformation of the kinase. It would be beneficial, however, to understand if AKB is susceptible to type II kinase inhibitors that bind to the inactive, DFG “out” conformation, since type II inhibitors achieve higher kinome selectivity and higher potency in vivo. The DFG “out” conformation of AKB is not yet experimentally determined which makes the design of type II inhibitors exceedingly difficult. An alternate approach is to simulate the DFG “out” conformation from the experimentally determined DFG “in” conformation using atomistic molecular dynamics (MD) simulation. In this work, we employed metadynamics (MTD) approach to simulate the DFG “out” conformation of AKB by choosing the appropriate collective variables. We examined structural changes during the DFG-flip and determined the interactions crucial to stabilize the kinase in active and inactive states. Interestingly, the MTD approach also identified a unique transition state (DFG “up”), which can be targeted by small molecule inhibitors. Structural insights about these conformations is essential for structure-guided design of next-generation AKB inhibitors. This work also emphasizes the usefulness of MTD simulations in predicting macromolecular conformational changes at reduced computational costs.
KW - Aurora kinase B
KW - DFG-in conformation
KW - DFG-out conformation
KW - metadynamics
UR - http://www.scopus.com/inward/record.url?scp=85076539919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076539919&partnerID=8YFLogxK
U2 - 10.1208/s12248-019-0399-6
DO - 10.1208/s12248-019-0399-6
M3 - Article
C2 - 31853739
AN - SCOPUS:85076539919
SN - 1550-7416
VL - 22
JO - AAPS Journal
JF - AAPS Journal
IS - 1
M1 - 14
ER -